OA11753A - Ketolide antibiotics. - Google Patents

Ketolide antibiotics. Download PDF

Info

Publication number: OA11753A
Authority: OA; OAPI
Prior art keywords: formula; compound; compounds; infection; group
Prior art date: 1999-01-27

Application number

OA1200100191A

Other languages

English (en)

Inventor

Takushi Kaneko

William Thomas Mcmillen

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-27

Filing date

1999-12-28

Publication date

2005-07-19

1999-12-28 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-07-19 Publication of OA11753A publication Critical patent/OA11753A/en

Links

239000003242 anti bacterial agent Substances 0.000 title abstract description 4
229940088710 antibiotic agent Drugs 0.000 title description 3
239000003835 ketolide antibiotic agent Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 109
208000015181 infectious disease Diseases 0.000 claims abstract description 45
238000000034 method Methods 0.000 claims abstract description 17
208000035143 Bacterial infection Diseases 0.000 claims abstract description 16
208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
125000005843 halogen group Chemical group 0.000 claims description 13
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
241000251468 Actinopterygii Species 0.000 claims description 10
241000124008 Mammalia Species 0.000 claims description 10
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 2
230000002140 halogenating effect Effects 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 21
230000001580 bacterial effect Effects 0.000 abstract description 7
208000035475 disorder Diseases 0.000 abstract description 7
206010037075 Protozoal infections Diseases 0.000 abstract description 6
239000003904 antiprotozoal agent Substances 0.000 abstract description 2
230000000844 anti-bacterial effect Effects 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
-1 azido, hydroxy Chemical group 0.000 description 27
125000000217 alkyl group Chemical group 0.000 description 21
125000002887 hydroxy group Chemical group [H]O* 0.000 description 15
239000000243 solution Substances 0.000 description 15
125000003118 aryl group Chemical group 0.000 description 13
239000003120 macrolide antibiotic agent Substances 0.000 description 12
239000000651 prodrug Substances 0.000 description 11
229940002612 prodrug Drugs 0.000 description 11
241000193996 Streptococcus pyogenes Species 0.000 description 10
238000003556 assay Methods 0.000 description 10
239000002585 base Substances 0.000 description 10
125000000623 heterocyclic group Chemical group 0.000 description 10
238000012360 testing method Methods 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
239000002253 acid Substances 0.000 description 9
101100119095 Enterococcus faecalis (strain ATCC 700802 / V583) ermB gene Proteins 0.000 description 8
239000000203 mixture Substances 0.000 description 8
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
241000283690 Bos taurus Species 0.000 description 7
241000193998 Streptococcus pneumoniae Species 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
125000004122 cyclic group Chemical group 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000002904 solvent Substances 0.000 description 7
241001293418 Mannheimia haemolytica Species 0.000 description 6
241000191967 Staphylococcus aureus Species 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
125000004093 cyano group Chemical group *C#N 0.000 description 6
229940031000 streptococcus pneumoniae Drugs 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
241000606856 Pasteurella multocida Species 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 4
241000271566 Aves Species 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
241000193985 Streptococcus agalactiae Species 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
125000003342 alkenyl group Chemical group 0.000 description 4
125000000304 alkynyl group Chemical group 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
150000001768 cations Chemical class 0.000 description 4
238000010511 deprotection reaction Methods 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
150000007524 organic acids Chemical class 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 4
238000013207 serial dilution Methods 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
241000282472 Canis lupus familiaris Species 0.000 description 3
241000193403 Clostridium Species 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
101150052154 MSRA1 gene Proteins 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
125000001153 fluoro group Chemical group F* 0.000 description 3
239000012458 free base Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
101150021123 msrA gene Proteins 0.000 description 3
101150114366 msrA2 gene Proteins 0.000 description 3
101150006794 msrAB gene Proteins 0.000 description 3
101150109310 msrAB1 gene Proteins 0.000 description 3
101150052209 msrAB2 gene Proteins 0.000 description 3
239000002674 ointment Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
244000052769 pathogen Species 0.000 description 3
208000028172 protozoa infectious disease Diseases 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
239000000126 substance Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241001148536 Bacteroides sp. Species 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
241001647372 Chlamydia pneumoniae Species 0.000 description 2
241000606153 Chlamydia trachomatis Species 0.000 description 2
241000194033 Enterococcus Species 0.000 description 2
241000194032 Enterococcus faecalis Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
241000588621 Moraxella Species 0.000 description 2
241000191992 Peptostreptococcus Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
206010062255 Soft tissue infection Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
241001312524 Streptococcus viridans Species 0.000 description 2
108010034396 Streptogramins Proteins 0.000 description 2
241000282898 Sus scrofa Species 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
239000008272 agar Substances 0.000 description 2
125000005907 alkyl ester group Chemical group 0.000 description 2
238000011203 antimicrobial therapy Methods 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
125000002393 azetidinyl group Chemical group 0.000 description 2
229960004099 azithromycin Drugs 0.000 description 2
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
229940038705 chlamydia trachomatis Drugs 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
101150016744 ermC gene Proteins 0.000 description 2
229960003276 erythromycin Drugs 0.000 description 2
235000019439 ethyl acetate Nutrition 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000028774 intestinal disease Diseases 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
239000002502 liposome Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229940041033 macrolides Drugs 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000017066 negative regulation of growth Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
150000002923 oximes Chemical group 0.000 description 2
239000006072 paste Substances 0.000 description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
159000000001 potassium salts Chemical class 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
206010040872 skin infection Diseases 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
208000019206 urinary tract infection Diseases 0.000 description 2
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
SEULWJSKCVACTH-UHFFFAOYSA-N 1-phenylimidazole Chemical compound C1=NC=CN1C1=CC=CC=C1 SEULWJSKCVACTH-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
241000606750 Actinobacillus Species 0.000 description 1
241000588986 Alcaligenes Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241001518086 Bartonella henselae Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000180135 Borrelia recurrentis Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
241001148534 Brachyspira Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
229910014585 C2-Ce Inorganic materials 0.000 description 1
125000000041 C6-C10 aryl group Chemical group 0.000 description 1
241000589875 Campylobacter jejuni Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
108010065152 Coagulase Proteins 0.000 description 1
241000224483 Coccidia Species 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
208000031973 Conjunctivitis infective Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
241000186227 Corynebacterium diphtheriae Species 0.000 description 1
241001518260 Corynebacterium minutissimum Species 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000605721 Dichelobacter nodosus Species 0.000 description 1
DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000520130 Enterococcus durans Species 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
229930006677 Erythromycin A Natural products 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
241000186394 Eubacterium Species 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010016952 Food poisoning Diseases 0.000 description 1
208000019331 Foodborne disease Diseases 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
241000605909 Fusobacterium Species 0.000 description 1
241000605952 Fusobacterium necrophorum Species 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241001148567 Lawsonia intracellularis Species 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
208000010315 Mastoiditis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000588622 Moraxella bovis Species 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100240347 Mus musculus Nectin2 gene Proteins 0.000 description 1
241000186367 Mycobacterium avium Species 0.000 description 1
241000513886 Mycobacterium avium complex (MAC) Species 0.000 description 1
241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
241000187478 Mycobacterium chelonae Species 0.000 description 1
241000186364 Mycobacterium intracellulare Species 0.000 description 1
241000186363 Mycobacterium kansasii Species 0.000 description 1
241000186362 Mycobacterium leprae Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241001138504 Mycoplasma bovis Species 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000605894 Porphyromonas Species 0.000 description 1
241000605861 Prevotella Species 0.000 description 1
102000055027 Protein Methyltransferases Human genes 0.000 description 1
108700040121 Protein Methyltransferases Proteins 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
208000019802 Sexually transmitted disease Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
241000191980 Staphylococcus intermedius Species 0.000 description 1
241000194042 Streptococcus dysgalactiae Species 0.000 description 1
201000005010 Streptococcus pneumonia Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000202921 Ureaplasma urealyticum Species 0.000 description 1
208000006374 Uterine Cervicitis Diseases 0.000 description 1
206010046793 Uterine inflammation Diseases 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
NYRAVIYBIHCEGB-UHFFFAOYSA-N [K].[Ca] Chemical compound [K].[Ca] NYRAVIYBIHCEGB-UHFFFAOYSA-N 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000002814 agar dilution Methods 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
229940092524 bartonella henselae Drugs 0.000 description 1
150000007514 bases Chemical class 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
229940000635 beta-alanine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940097269 borrelia burgdorferi Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
206010008323 cervicitis Diseases 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000005660 chlorination reaction Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229910052681 coesite Inorganic materials 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229910052906 cristobalite Inorganic materials 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
201000010251 cutis laxa Diseases 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
125000000532 dioxanyl group Chemical group 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
229940009662 edetate Drugs 0.000 description 1
229950005627 embonate Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
229940032049 enterococcus faecalis Drugs 0.000 description 1
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
229950000206 estolate Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
229940050411 fumarate Drugs 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000003838 furazanyl group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
229960001731 gluceptate Drugs 0.000 description 1
KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
208000020673 hypertrichosis-acromegaloid facial appearance syndrome Diseases 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
229940099584 lactobionate Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
229940041028 lincosamides Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
229940049920 malate Drugs 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
208000004396 mastitis Diseases 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
101150111763 mefA gene Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003551 oxepanyl group Chemical group 0.000 description 1
125000003566 oxetanyl group Chemical group 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
229940051027 pasteurella multocida Drugs 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000005541 phosphonamide group Chemical group 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000002755 pyrazolinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
JQRYUMGHOUYJFW-UHFFFAOYSA-N pyridine;trihydrobromide Chemical compound [Br-].[Br-].[Br-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 JQRYUMGHOUYJFW-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
150000007660 quinolones Chemical class 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000006268 reductive amination reaction Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000012363 selectfluor Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910052682 stishovite Inorganic materials 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
229940076156 streptococcus pyogenes Drugs 0.000 description 1
229940041030 streptogramins Drugs 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001583 thiepanyl group Chemical group 0.000 description 1
125000002053 thietanyl group Chemical group 0.000 description 1
238000003354 tissue distribution assay Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
206010044008 tonsillitis Diseases 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
229910052905 tridymite Inorganic materials 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
150000003952 β-lactams Chemical class 0.000 description 1
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Gynecology & Obstetrics (AREA)
Biotechnology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Pregnancy & Childbirth (AREA)
Otolaryngology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Tropical Medicine & Parasitology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Cephalosporin Compounds (AREA)

OA1200100191A 1999-01-27 1999-12-28 Ketolide antibiotics. OA11753A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11734299P	1999-01-27	1999-01-27

Publications (1)

Publication Number	Publication Date
OA11753A true OA11753A (en)	2005-07-19

Family

ID=22372371

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100191A OA11753A (en)	1999-01-27	1999-12-28	Ketolide antibiotics.

Country Status (39)

Country	Link
US (1)	US6833444B2 (id)
EP (1)	EP1147121B1 (id)
JP (1)	JP3947360B2 (id)
KR (1)	KR20020002380A (id)
CN (1)	CN1342163A (id)
AP (1)	AP2001002222A0 (id)
AT (1)	ATE256694T1 (id)
AU (1)	AU1675400A (id)
BG (1)	BG105730A (id)
BR (1)	BR9916969A (id)
CA (1)	CA2359708C (id)
CO (1)	CO5150229A1 (id)
CZ (1)	CZ20012675A3 (id)
DE (1)	DE69913738T2 (id)
DK (1)	DK1147121T3 (id)
DZ (1)	DZ3000A1 (id)
EA (1)	EA200100623A1 (id)
EE (1)	EE200100394A (id)
ES (1)	ES2212655T3 (id)
HK (1)	HK1042707A1 (id)
HN (1)	HN2000000003A (id)
HR (1)	HRP20010559A2 (id)
HU (1)	HUP0105190A3 (id)
ID (1)	ID30233A (id)
IL (1)	IL144178A0 (id)
IS (1)	IS5984A (id)
MA (1)	MA26717A1 (id)
NO (1)	NO20013680L (id)
OA (1)	OA11753A (id)
PA (1)	PA8489501A1 (id)
PE (1)	PE20001422A1 (id)
PT (1)	PT1147121E (id)
SI (1)	SI1147121T1 (id)
SK (1)	SK10172001A3 (id)
TN (1)	TNSN00007A1 (id)
TR (1)	TR200102128T2 (id)
UY (1)	UY25990A1 (id)
WO (1)	WO2000044761A2 (id)
ZA (1)	ZA200105580B (id)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP1060A (en)	1998-01-02	2002-04-23	Pfizer Prod Inc	Novel erythromycin derivatives.
CA2359708C (en)	1999-01-27	2005-10-25	Pfizer Products Inc.	Ketolide antibiotics
US6514944B2 (en)	1999-04-16	2003-02-04	Kosan Biosciences, Inc.	Macrolide antiinfective agents
US6451768B1 (en)	1999-04-16	2002-09-17	Kosan Biosciences, Inc.	Macrolide antiinfective agents
ID30547A (id) *	1999-04-16	2001-12-20	Kosan Biosciences Inc	Zat anti-infeksi makrolida
US6939861B2 (en)	1999-04-16	2005-09-06	Kosan Biosciences, Inc.	Amido macrolides
US6590083B1 (en)	1999-04-16	2003-07-08	Ortho-Mcneil Pharmaceutical, Inc.	Ketolide antibacterials
IL145976A0 (en)	1999-04-16	2002-07-25	Ortho Mcneil Pharm Inc	Ketolide antibacterials
EA200100983A1 (ru)	1999-05-24	2002-10-31	Пфайзер Продактс Инк.	Производные 13-метилэритромицина
DE60104240T2 (de)	2000-06-30	2005-08-04	Pfizer Products Inc., Groton	Makrolid-Antibiotika
US20020115621A1 (en)	2000-08-07	2002-08-22	Wei-Gu Su	Macrolide antibiotics
CN1492874A (zh) *	2000-12-21	2004-04-28		大环内酯
PE20030438A1 (es) *	2001-09-05	2003-07-03	Hokuriku Pharmaceutical	Medicamento que comprende un derivado de eritromicina como agente antituberculoso
ES2552682T3 (es)	2003-03-10	2015-12-01	Merck Sharp & Dohme Corp.	Agentes antibacterianos novedosos
JP2008508322A (ja) *	2004-07-28	2008-03-21	ランバクシーラボラトリーズリミテッド	抗菌剤としてのケトライド誘導体
UA85937C2 (uk)	2004-12-21	2009-03-10	Пфайзер Продактс Інк.	Макроліди
RU2455308C2 (ru) *	2006-05-01	2012-07-10	Тайсо Фармасьютикал Ко., Лтд.	Макролидные производные
CN105732745A (zh)	2007-10-25	2016-07-06	森普拉制药公司	大环内酯类抗菌剂的制备方法
AU2009308182B2 (en)	2008-10-24	2016-05-19	Cempra Pharmaceuticals, Inc.	Biodefenses using triazole-containing macrolides
US9937194B1 (en)	2009-06-12	2018-04-10	Cempra Pharmaceuticals, Inc.	Compounds and methods for treating inflammatory diseases
US9480679B2 (en)	2009-09-10	2016-11-01	Cempra Pharmaceuticals, Inc.	Methods for treating malaria, tuberculosis and MAC diseases
DK2550286T3 (en)	2010-03-22	2016-02-29	Cempra Pharmaceuticals Inc	CRYSTALLINE FORMS OF A MACROLID AND APPLICATIONS THEREOF
CN105198944B (zh)	2010-05-20	2018-06-01	森普拉制药公司	制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (en)	2010-09-10	2014-01-15	Cempra Pharmaceuticals Inc	HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
MX2014011537A (es)	2012-03-27	2015-02-10	Cempra Pharmaceuticals Inc	Formulaciones parenterales para la administracion de antibioticos macrolidos.
HK1217665A1 (zh)	2013-03-14	2017-01-20	森普拉制药公司	用於治療呼吸道疾病的方法及其製劑
RU2015138797A (ru)	2013-03-15	2017-04-24	Семпра Фармасьютикалс, Инк.	Конвергентные способы получения макролидных антибактериальных агентов
US10390544B2 (en)	2013-03-28	2019-08-27	Fuji Oil Company Limited	Mung bean protein gel composition and cheese-like food
CN106518939B (zh) *	2015-09-14	2019-12-31	江苏奥赛康药业有限公司	一种制备Solithromycin化合物的方法
JP2019533669A (ja) *	2016-10-04	2019-11-21	バイオファーマティソシエテアノニム	抗菌活性を有するケトライド

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI8110592A8 (en) *	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5141926A (en) *	1990-04-18	1992-08-25	Abbott Laboratories	Erythromycin derivatives
IL114589A (en)	1990-11-21	1999-12-22	Roussel Uclaf	Intermediates for the preparation of erythromycin derivatives
FR2697524B1 (fr)	1992-11-05	1994-12-23	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en)	1992-11-05	1996-06-18	Roussel Uclaf	Erythromycin derivatives
FR2719587B1 (fr) *	1994-05-03	1996-07-12	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2727969B1 (fr) *	1994-12-09	1997-01-17	Roussel Uclaf	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5747466A (en) *	1995-11-08	1998-05-05	Abbott Laboratories	3-deoxy-3-descladinose derivatives of erythromycins A and B
FR2742757B1 (fr) *	1995-12-22	1998-01-30	Roussel Uclaf	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr)	1996-02-28	1998-04-03	Roussel Uclaf	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2748746B1 (fr)	1996-05-14	1998-08-14	Hoechst Marion Roussel Inc	Nouveau procede d'isomerisation du radical methyle en 10 de derives de l'erythromycine
AP1029A (en)	1996-07-05	2001-12-11	Biotica Tech Limited	Erythromycins and process for their preparation.
FR2751656B1 (fr)	1996-07-24	1998-10-16	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
UA51730C2 (uk)	1996-09-04	2002-12-16	Ебботт Лабораторіз	6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
FR2757168B1 (fr)	1996-12-12	1999-06-11	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2760017B1 (fr)	1997-02-27	1999-04-30	Hoechst Marion Roussel Inc	Nouveaux derives de l'erytromycine, leur procede de preparation et leur application comme medicaments
WO1998040392A1 (fr)	1997-03-10	1998-09-17	Taisho Pharmaceutical Co., Ltd.	Derives d'erythromycine a
US20020025937A1 (en)	2000-03-20	2002-02-28	Yong-Jin Wu	9-oxime erythromycin derivatives
ZA987689B (en)	1997-09-02	1999-02-24	Abbott Lab	3-descladinose 6-O substituted erythromycin derivatives
ZA989835B (en)	1997-10-29	1999-05-05	Taisho Pharmaceutical Co Ltd	Erythromycin a derivatives
HN1998000159A (es)	1997-10-29	1999-02-09	Monsanto Co	Derivados de 9- amino - 3 ceto eritromicina
WO1999025385A1 (en)	1997-11-17	1999-05-27	Imarx Pharmaceutical Corp.	A method of increasing nucleic acid synthesis with ultrasound
FR2771008B1 (fr) *	1997-11-17	2000-04-28	Hoechst Marion Roussel Inc	Utilisation des ketolides pour la preparation de compositions pharmaceutiques destinees a prevenir les complications thrombotiques arterielles liees a l'atherosclerose
AP1060A (en)	1998-01-02	2002-04-23	Pfizer Prod Inc	Novel erythromycin derivatives.
FR2777282B1 (fr)	1998-04-08	2001-04-20	Hoechst Marion Roussel Inc	Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
WO2000017218A1 (en)	1998-09-22	2000-03-30	Pfizer Products Inc.	Carbamate and carbazate ketolide antibiotics
US6100240A (en) *	1998-10-09	2000-08-08	Pfizer Inc	Macrolide derivatives
FR2785612A1 (fr) *	1998-11-10	2000-05-12	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR20010083944A (ko)	1998-11-03	2001-09-03	실버스타인 아써 에이.	신규 마크롤라이드 항생물질
FR2786188B1 (fr) *	1998-11-24	2002-10-31	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
TR200102129T2 (tr) *	1998-12-10	2002-01-21	Pfizer Products Inc.	Karbamat ve karbazat ketolid antibiyotikleri.
CA2359708C (en)	1999-01-27	2005-10-25	Pfizer Products Inc.	Ketolide antibiotics
FR2789392B1 (fr)	1999-02-04	2001-10-05	Hoechst Marion Roussel Inc	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ID30547A (id)	1999-04-16	2001-12-20	Kosan Biosciences Inc	Zat anti-infeksi makrolida
IL145976A0 (en)	1999-04-16	2002-07-25	Ortho Mcneil Pharm Inc	Ketolide antibacterials
US6355620B1 (en)	1999-05-14	2002-03-12	Abbott Laboratories	C-2 modified erythromycin derivatives
EA200100983A1 (ru)	1999-05-24	2002-10-31	Пфайзер Продактс Инк.	Производные 13-метилэритромицина
EP1114826A3 (en)	1999-12-29	2001-10-31	Pfizer Products Inc.	Novel antibacterial and prokinetic macrolides
EP1122261A3 (en)	2000-01-31	2001-09-26	Pfizer Products Inc.	13 and 14-membered antibacterial macrolides
US20020061856A1 (en)	2000-04-24	2002-05-23	Yong-Jin Wu	Novel tricyclic erythromycin derivatives
DE60104240T2 (de)	2000-06-30	2005-08-04	Pfizer Products Inc., Groton	Makrolid-Antibiotika

1999
- 1999-12-28 CA CA002359708A patent/CA2359708C/en not_active Expired - Fee Related
- 1999-12-28 BR BR9916969-0A patent/BR9916969A/pt not_active Application Discontinuation
- 1999-12-28 SI SI9930486T patent/SI1147121T1/xx unknown
- 1999-12-28 ID IDW00200101637A patent/ID30233A/id unknown
- 1999-12-28 IL IL14417899A patent/IL144178A0/xx unknown
- 1999-12-28 WO PCT/IB1999/002051 patent/WO2000044761A2/en not_active Ceased
- 1999-12-28 HK HK02104131.0A patent/HK1042707A1/zh unknown
- 1999-12-28 OA OA1200100191A patent/OA11753A/en unknown
- 1999-12-28 ES ES99959627T patent/ES2212655T3/es not_active Expired - Lifetime
- 1999-12-28 AP APAP/P/2001/002222A patent/AP2001002222A0/en unknown
- 1999-12-28 AU AU16754/00A patent/AU1675400A/en not_active Abandoned
- 1999-12-28 EP EP99959627A patent/EP1147121B1/en not_active Expired - Lifetime
- 1999-12-28 JP JP2000596017A patent/JP3947360B2/ja not_active Expired - Fee Related
- 1999-12-28 KR KR1020017009382A patent/KR20020002380A/ko not_active Ceased
- 1999-12-28 SK SK1017-2001A patent/SK10172001A3/sk unknown
- 1999-12-28 HU HU0105190A patent/HUP0105190A3/hu unknown
- 1999-12-28 DE DE69913738T patent/DE69913738T2/de not_active Expired - Lifetime
- 1999-12-28 EA EA200100623A patent/EA200100623A1/ru unknown
- 1999-12-28 CZ CZ20012675A patent/CZ20012675A3/cs unknown
- 1999-12-28 TR TR2001/02128T patent/TR200102128T2/xx unknown
- 1999-12-28 PT PT99959627T patent/PT1147121E/pt unknown
- 1999-12-28 AT AT99959627T patent/ATE256694T1/de not_active IP Right Cessation
- 1999-12-28 DK DK99959627T patent/DK1147121T3/da active
- 1999-12-28 CN CN99815909A patent/CN1342163A/zh active Pending
- 1999-12-28 HR HR20010559A patent/HRP20010559A2/hr not_active Application Discontinuation
- 1999-12-28 EE EEP200100394A patent/EE200100394A/xx unknown
2000
- 2000-01-05 TN TNTNSN00007A patent/TNSN00007A1/fr unknown
- 2000-01-05 DZ DZ000002A patent/DZ3000A1/xx active
- 2000-01-06 PE PE2000000013A patent/PE20001422A1/es not_active Application Discontinuation
- 2000-01-06 MA MA25883A patent/MA26717A1/fr unknown
- 2000-01-06 PA PA20008489501A patent/PA8489501A1/es unknown
- 2000-01-06 HN HN2000000003A patent/HN2000000003A/es unknown
- 2000-01-21 CO CO00003460A patent/CO5150229A1/es unknown
- 2000-01-27 UY UY25990A patent/UY25990A1/es unknown
2001
- 2001-06-28 IS IS5984A patent/IS5984A/is unknown
- 2001-07-06 ZA ZA200105580A patent/ZA200105580B/en unknown
- 2001-07-25 BG BG105730A patent/BG105730A/xx unknown
- 2001-07-26 NO NO20013680A patent/NO20013680L/no not_active Application Discontinuation
2002
- 2002-04-05 US US10/116,969 patent/US6833444B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU1675400A (en)	2000-08-18
UY25990A1 (es)	2000-09-29
HRP20010559A2 (en)	2002-08-31
US6833444B2 (en)	2004-12-21
CZ20012675A3 (cs)	2002-04-17
EP1147121A2 (en)	2001-10-24
EE200100394A (et)	2002-10-15
NO20013680L (no)	2001-09-19
WO2000044761A3 (en)	2001-01-04
ID30233A (id)	2001-11-15
EA200100623A1 (ru)	2002-02-28
AP2001002222A0 (en)	2001-09-30
PA8489501A1 (es)	2000-09-29
IS5984A (is)	2001-06-28
JP3947360B2 (ja)	2007-07-18
KR20020002380A (ko)	2002-01-09
TNSN00007A1 (fr)	2005-11-10
CA2359708C (en)	2005-10-25
DE69913738T2 (de)	2004-06-17
HK1042707A1 (zh)	2002-08-23
ZA200105580B (en)	2003-02-17
CN1342163A (zh)	2002-03-27
JP2002535414A (ja)	2002-10-22
IL144178A0 (en)	2002-05-23
DK1147121T3 (da)	2004-04-13
HUP0105190A3 (en)	2003-03-28
DZ3000A1 (fr)	2004-03-27
WO2000044761A2 (en)	2000-08-03
TR200102128T2 (tr)	2001-12-21
ATE256694T1 (de)	2004-01-15
US20020156027A1 (en)	2002-10-24
HN2000000003A (es)	2001-02-02
MA26717A1 (fr)	2004-12-20
CO5150229A1 (es)	2002-04-29
DE69913738D1 (de)	2004-01-29
SK10172001A3 (sk)	2002-06-04
CA2359708A1 (en)	2000-08-03
BR9916969A (pt)	2001-11-06
BG105730A (en)	2002-03-29
ES2212655T3 (es)	2004-07-16
PE20001422A1 (es)	2000-12-18
EP1147121B1 (en)	2003-12-17
PT1147121E (pt)	2004-04-30
NO20013680D0 (no)	2001-07-26
SI1147121T1 (en)	2004-04-30
HUP0105190A2 (hu)	2002-04-29

Publication	Publication Date	Title
OA11753A (en)	2005-07-19	Ketolide antibiotics.
US6664238B1 (en)	2003-12-16	Carbamate and carbazate ketolide antibiotics
EP1132392B1 (en)	2004-03-03	Ketolide antibiotics
US6329345B1 (en)	2001-12-11	13-membered azalides and their use as antibiotic agents
CA2351829C (en)	2006-01-17	Macrolide antibiotics
CA2343344A1 (en)	2001-10-10	Erythromycin a derivatives
EP1115732B1 (en)	2005-06-29	Carbamate and carbazate ketolide antibiotics
US20020077302A1 (en)	2002-06-20	Tricyclic erythromycin derivatives
EP1298138B1 (en)	2006-11-02	Carbamate and Carbazate Ketolide Antibiotics
MXPA01007584A (en)	2002-05-09	Ketolide antibiotics
MXPA01002355A (en)	2002-06-05	Ketolide antibiotics
EP1749832A2 (en)	2007-02-07	Carbamate and carbazate ketolide antibiotics
MXPA01005055A (en)	2001-12-04	13-membered azalides and their use as antibiotic agents